TxCell reports results from annual general meeting of shareholders

May 28 2015

TxCell SA (FR0010127662 – TXCL), a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, today announces results of its annual general meeting of shareholders held in Valbonne, France.

The quorum amounted to over 85 per cent, with a number of 9,965,370 expressed votes, out of a total 11,644,695 voting rights.

All resolutions were voted in accordance with recommendations from the board of directors.

Details of votes are available on the company’s website: www.txcell-finance.com.

During the meeting, Mr. Thibaut Roulon, was appointed a member of the board of directors as a representative of Bpifrance Participations.

“The general meeting was a good opportunity for the shareholders to reiterate their support to the strategy set by the board of directors and executed by the management at TxCell,” said François Meyer, Chairman of the Board of Directors, TxCell. “Combining a solid scientific grounding, more than 115 patents, a platform with the first two innovative products in development and a first pharma partnership, TxCell has all the ingredients to succeed in at an ideal time where cellular immunotherapy is rapidly gaining momentum.”

“As explained today to our shareholders, Ovasave(R), our lead product, is currently being tested in one of the most ambitious clinical trials ever conducted in Europe with a personalized cellular therapy product. We expect data from this trial, conducted in refractory Crohn’s disease, in 2017. These data will be important for the further validation of ASTrIA, our first product platform of antigen specific regulatory T-cells (Ag-Tregs),” said Stéphane Boissel, CEO, TxCell. “Encouraged by this pioneering work on regulatory T cells, a second innovative product platform based on engineered regulatory T cells (CAR-Treg) is currently being explored. This platform would be a good complement to ASTrIA as it would broaden the scope of diseases addressable by TxCell’s technologies, for the benefits of the medical community and of patients.”